Kieran Wynne

Kieran Wynne

Auto-generated profile, based on publicly available information

Kieran Wynne

Systems Biology Ireland, School of Medicine, University College Dublin, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2012 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
GBGerard L Brien
Gerard L Brien
GGGuillermo Gambero
Guillermo Gambero
DOdavid o'connell
david o'connell
EJEmilia Jerman
Emilia Jerman
STSiobhán A Turner
Siobhán A Turner
ABAdrian P Bracken
Adrian P Bracken

1 April 2007 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
MSMichael Scannell
Michael Scannell
MFMichelle B. Flanagan
Michelle B. Flanagan
ADAndreas Destefani
Andreas Destefani
KWKieran J. Wynne
Kieran J. Wynne
GCGerard Cagney
Gerard Cagney
PMPaola Maderna
Paola Maderna
The resolution of inflammation is a dynamically regulated process that may be subverted in many pathological conditions. Macrophage (Mφ) phagocytic clearance of apoptotic leukocytes plays an important role in the resolution of inflammation as this process prevents the exposure of tissues at the inflammatory site to the noxious contents of lytic cells. It is increasingly appreciated that endogenously produced mediators, such as lipoxins, act as potent regulators (nanomolar range) of the phagocytic clearance of apoptotic cells. In this study, we have investigated the intriguing possibility that apoptotic cells release signals that promote their clearance by phagocytes. We report that conditioned medium from apoptotic human polymorphonuclear neutrophils (PMN), Jurkat T lymphocytes, and human mesangial cells promote phagocytosis of apoptotic PMN by Mφ and THP-1 cells differentiated to a Mφ-like phenotype. This prophagocytic activity appears to be dose dependent, sensitive to the caspase inhibitor zVAD-fmk, and is associated with actin rearrangement and release of TGF-β1, but not IL-8. The prophagocytic effect can be blocked by the formyl peptide receptor antagonist Boc2, suggesting that the prophagocytic factor(s) may interact with the lipoxin A4 receptor, FPRL-1. Using nanoelectrospray liquid chromatography mass spectrometry and immunodepletion and immunoneutralization studies, we have ascertained that annexin-1 and peptide derivatives are putative prophagocytic factors released by apoptotic cells that promote phagocytosis of apoptotic PMN by M[phi] and differentiated THP-1 cells. These data highlight the role of annexin-1 and peptide derivatives in promoting the resolution of inflammation and expand on the therapeutic anti-inflammatory potential of annexin-1.

15 November 2018 in eLife
Verified
Journal Article
Open access
GBGerard L Brien
Gerard L Brien
DRDavid Remillard
David Remillard
JSJunwei Shi
Junwei Shi
MHMatthew L Hemming
Matthew L Hemming
JCJonathon Chabon
Jonathon Chabon
SAScott A Armstrong
Scott A Armstrong
Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component of SS18-SSX containing BAF complexes in synovial sarcoma cells; and integration of BRD9 into these complexes is critical for cell growth. Moreover BRD9 and SS18-SSX co-localize extensively on the synovial sarcoma genome. Remarkably, synovial sarcoma cells are highly sensitive to a novel small molecule degrader of BRD9, while other sarcoma subtypes are unaffected. Degradation of BRD9 induces downregulation of oncogenic transcriptional programs and inhibits tumour progression in vivo. We demonstrate that BRD9 supports oncogenic mechanisms underlying the SS18-SSX fusion in synovial sarcoma and highlight targeted degradation of BRD9 as a potential therapeutic opportunity in this disease.

22 July 2014 in Molecular Psychiatry
Verified
Journal Article
Closed access
PDF file
MFM Föcking
M Föcking
LLL M Lopez
L M Lopez
JEJ A English
J A English
PDP Dicker
P Dicker
AWA Wolff
A Wolff
DCD R Cotter
D R Cotter

1 June 2002 in Proteomics
Verified
Journal Article
Closed access
PDF file
PMPatricia B Maguire
Patricia B Maguire
KWKieran J. Wynne
Kieran J. Wynne
DHDonal F. Harney
Donal F. Harney
NONiaobh M. O'Donoghue
Niaobh M. O'Donoghue
GSGillian Stephens
Gillian Stephens
DFDesmond J. Fitzgerald
Desmond J. Fitzgerald

20 October 2015 in Translational Psychiatry
Verified
Journal Article
Open access
PDF file
JEJ A English
J A English
YFY Fan
Y Fan
MFM Föcking
M Föcking
LLL M Lopez
L M Lopez
MHM Hryniewiecka
M Hryniewiecka
DCD R Cotter
D R Cotter
Human olfactory neurosphere-derived (ONS) cells have the potential to provide novel insights into the cellular pathology of schizophrenia. We used discovery-based proteomics and targeted functional analyses to reveal reductions in 17 ribosomal proteins, with an 18% decrease in the total ribosomal signal intensity in schizophrenia-patient-derived ONS cells. We quantified the rates of global protein synthesis in vitro and found a significant reduction in the rate of protein synthesis in schizophrenia patient-derived ONS cells compared with control-derived cells. Protein synthesis rates in fibroblast cell lines from the same patients did not differ, suggesting cell type-specific effects. Pathway analysis of dysregulated proteomic and transcriptomic data sets from these ONS cells converged to highlight perturbation of the eIF2α, eIF4 and mammalian target of rapamycin (mTOR) translational control pathways, and these pathways were also implicated in an independent induced pluripotent stem cell-derived neural stem model, and cohort, of schizophrenia patients. Analysis in schizophrenia genome-wide association data from the Psychiatric Genetics Consortium specifically implicated eIF2α regulatory kinase EIF2AK2, and confirmed the importance of the eIF2α, eIF4 and mTOR translational control pathways at the level of the genome. Thus, we integrated data from proteomic, transcriptomic, and functional assays from schizophrenia patient-derived ONS cells with genomics data to implicate dysregulated protein synthesis for the first time in schizophrenia.